Home / Business and Economy / Weight Loss Drugs Vie for China Insurance Inclusion
Weight Loss Drugs Vie for China Insurance Inclusion
29 Jun
Summary
- Two GLP-1 drugs passed a preliminary review for China's insurance list.
- Both drugs treat type II diabetes and aid in weight management.
- Only diabetes treatment is eligible for China's medical insurance.
Two significant GLP-1 receptor agonist drugs, Pfizer's ecnoglutide and Innovent Biologics' mazdutidie, have successfully navigated a preliminary review. This step potentially allows for their inclusion in China's national medical insurance drug catalogue. Both medications are currently approved within China for two key health areas: managing type II diabetes and assisting with weight management.
While the review progresses, a spokesperson for Innovent clarified a crucial aspect of insurance coverage in China. This clarification indicates that from a medical insurance perspective, only the diabetes treatment application of these drugs would be considered for inclusion in the national list. Further details on the final outcome of the review are pending.
